We are Synthetic Biology

DNA2.0 has been the industry leader in Synthetic Biology Solutions for over a decade.
Our products, consultants and services enable researchers worldwide to achieve their goals.

Company Management bobbleheads

Jon Ness, Sridhar Govindarajan, Jeremy Minshull and Claes Gustafsson

With significant industry experience in fields such as molecular biology, bioinformatics, technology development and research leadership, the company’s senior management team uniquely positions DNA2.0 as an industry-leading enabler of visionary products and services. DNA2.0’s visionary biotech leadership has improved the way people research, create and live, one gene at a time.

Sridhar Govindarajan, Ph.D.

Chief Information Officer

As DNA2.0’s Co-founder and CIO, Dr. Sridhar Govindarajan leads the company’s automation and protein engineering efforts. He offers more than 20 years of scientific computing experience. Prior to his current position, Govindarajan led the computational research in optimizing directed evolution technologies at Maxygen, Inc., and was a Systems Architect at EraGen Biosciences. Govindarajan conducted graduate-level research at the University of Michigan’s Department of Chemistry, and was a Junior Research Fellow at the Indian Institute of Technology (IIT)’s Department of Chemistry. In addition to his role at DNA2.0, Govindarajan contributes to the science community through industry event presentations and the publishing of more than 40 papers, including a 2008 peer-reviewed paper in Nature. He received his Ph.D. in Computational Chemistry/Biophysics from the University of Michigan and holds an undergraduate degree in Chemistry from IIT in Mumbai, India.

Claes Gustafsson, Ph.D.

Chief Commercial Officer

As DNA2.0’s Co-Founder and CCO, Dr. Gustafsson oversees most of the company’s external communications. Prior to co-founding DNA2.0, Gustafsson was Scientist and later Manager at Maxygen Inc., where he led, managed and collaborated with key strategic teams for more than five years. He also held a Scientist position at Kosan Biosciences, as well as a number of research, teaching, and post-doctoral positions at UCs Santa Cruz and San Francisco, and at University of Umeå. He holds 43 issued U.S. patents and has published >40 scientific papers. Gustafsson received his Ph.D. in Molecular Biology/Biochemistry from the University of Umeå, Sweden (Heja Löven) where he studied translation under Prof Glenn Björk.

James Love, Ph.D.

Director, Expression Technologies

Dr. James Love joined DNA2.0 in 2015 as Director of Expression Technologies to spearhead the development of protein services that DNA2.0 now offers, at our new 50,000 sq ft facility in Newark, CA. James was trained as a structural biologist at the MRC-LMB in Cambridge, UK before postdoctoral work at Columbia University. He went on to become the Head of Research at the New York Consortium on Membrane Protein Structures where he developed high-throughput methods for producing integral membrane proteins. He then joined the New York Consortium Structural Genomics Research Consortium where he developed methods for the production of human proteins in mammalian cells. He is an author on 35 publications, including several in Nature, and is an author on over 450 protein structures.

Jeremy Minshull, Ph.D.

Chief Executive Officer

Dr. Jeremy Minshull has served as President/CEO of DNA2.0 since co-founding the company in 2003. Previously, he was Vice President of Core Technology at Maxygen Inc., where he developed new technologies and scientific infrastructure to support directed evolution projects in chemical, agricultural and human therapeutic areas. He also held an early position at Affymax, where he helped develop and enable DNA shuffling. Dr. Minshull has received several industry awards, holds 54 patents, is a member of several professional societies, and has authored or co-authored >40 peer-reviewed papers. Dr. Minshull was a post-doctoral fellow at UC San Francisco, and received his Ph.D. from the University of Cambridge, where he studied basic control of the eukaryotic cell cycle with Nobel laureate Dr. Tim Hunt. Minshull received an honors degree in Natural Sciences (Biochemistry) from Sidney Sussex College, University of Cambridge, England.

Jon Ness, Ph.D.

Chief Scientific Officer

Dr. Jon Ness is a co-founder of DNA2.0 and has coordinated the DNA2.0 technology development since its inception. Prior to his tenure at DNA2.0, Ness was one of the first employees at Maxygen Inc., where he led Maxygen’s DNA Shuffling Technology Development Group. He also served as project leader for Maxygen’s collaborative partnership with Novozymes, focusing on improving industrial enzymes, including the laundry detergent protease subtilisin. As a post-doctoral fellow at Affymax, Ness laid the groundwork for in vivo recombination and whole genome shuffling in microorganisms. Dr. Ness holds 18 patents and is the co-author of 10 peer-reviewed articles. He received a Ph.D. in Bacterial Genetics and Physiology from UC Davis, and a BS in Microbiology from the University of Minnesota.

Walter Tian, M.S., M.B.A.

SVP, Marketing & Corporate Strategy

Walter Tian joined DNA2.0 in September 2011. As Senior Vice President for Marketing and Corporate Strategy, he leads DNA2.0’s sales and marketing activities in delivering high-quality and high-content gene synthesis services. Mr. Tian has more than seven years’ experience in biotechnology research and over 18 years in marketing and business management in the life sciences. Most recently, Mr. Tian was Vice President for Marketing at OriGene Technologies, Inc., where he led the marketing and product development efforts in transitioning the company’s business from cDNA products to complete gene-centric research solutions. Prior to OriGene, Mr. Tian spent five years as Global Business Director at QIAGEN, leading a global business unit focused on siRNA and miRNA portfolio development. Mr. Tian also has held management positions at PerkinElmer, Endogen, and T Cell Sciences. Mr. Tian received his MBA degree from Northeastern University, MS degree from Beijing Medical University, and a medical degree from Xi’An Medical College.

DNA2.0 is the leading bioengineering solutions provider. Founded in 2003, DNA2.0 offers an integrated pipeline of solutions for the research community, including platforms for protein and vector engineering, products such as expression vectors, fluorescent and chromogenic proteins, cell strains and reagents, as well as gene design, optimization, synthesis and cloning. DNA2.0 is based in the US, with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 is by far the most published synthetic biology vendor, providing expert support to and collaboration with scientists. The company is privately held and is headquartered in Newark, California

With a reverence for the interplay between science, technology and nature, DNA2.0 has developed a unique engineering platform based on machine learning and Design of Experiment (DoE).  The ProteinGPS® proprietary protein engineering technology uses megadimensional, empirical optimization processes to calculate the set of nodes that are information-rich in the relevant space, gene synthesis to make those exact sequences, and machine learning to find the preferred solution. The result: precise engineering of any measurable property in any protein so that it fulfills the exact functional criteria needed for commercialization. The proprietary VectorGPS® technology uses Design-of-Experiment (DoE) algorithms to build testable numbers of vectors from sets of control elements, and advanced machine learning to assess the contribution of each element to vector performance; resulting in custom vectors engineered precisely for individual proteins and expression systems.

While leading the industry in creating value-added applications through protein engineering, vector design and gene synthesis, DNA2.0 has also chosen to emphasize customer service as a critical measure of success. The freely available DNA2.0 software tool Gene Designer and the online DNA ATLAS, put all the tools and expertise needed for DNA sequence management and design at the fingertips of the user. The company positions itself as a resource and research partner for its customers, to enable accurate and innovative delivery of specific, immediately useful solutions. Customers value the individual, Ph.D.-level support they receive from DNA2.0’s sales and support staff, as well as the speed, accuracy, and flexibility with which products and services are delivered.

DNA2.0 Issued Patents DNA2.0 scientists are noted in italics

  • 9,290,552 Fluorescent and colored proteins and methods for using them. Minshull and Theodorou

  • 9,206,433 Methods, compositions and kits for a one-step DNA cloning system. Minshull, Ness and Theodorou

  • 9,102,944 Methods, compositions and kits for one-step DNA cloning using DNA topoisomerase. Ness and Minshull

  • 8,975,042 Fluorescent and colored proteins and methods for using them. Minshull and Theodorou

  • 8,825,411 Design, synthesis and assembly of synthetic nucleic acids. Govindarajan, Minshull and Ness

  • 8,635,029 Systems and methods for biopolymer engineering. Gustafsson, Govindarajan and Minshull

  • 8,412,461 Systems and methods for antibody engineering. Gustafsson, Govindarajan and Minshull.

  • 8,401,798 Systems and methods for constructing frequency lookup tables for expression systems. Welch and Gustafsson.

  • 8,323,930 Methods, compositions and kits for one-step DNA cloning using DNA topoisomerase. Ness and Minshull.

  • 8,158,391 Production of an α-carboxyl-ω-hydroxy fatty acid using a genetically modified Candida strain. Gross, Lu, Ness and Minshull.

  • 8,126,653 Synthetic nucleic acids for expression of encoded proteins. Welch and Gustafsson.

  • 8,005,620 Systems and methods for biopolymer engineering. Gustafsson, Govindarajan and Minshull.

  • 7,805,252 Systems and methods for designing and ordering polynucleotides. Gustafsson, Govindarajan, Ness, Villalobos and Minshull.

  • 7,561,973 Methods for determining properties that affect an expression property value of polynucleotides in an expression system. Welch and Gustafsson.

  • 7,561,972 Synthetic nucleic acids for expression of encoded proteins. Welch and Gustafsson.

DNA2.0 Publications

View all published articles from researchers at DNA2.0

Search the DNA2.0 Literature Database, containing over 1,200 scientific publications using DNA2.0 technology for references relevant to your research.

DNA2.0 Holiday Publications

Proc Natl Acad Sci Northpole 2015. 12:25-31. Optimization of Eggnog using Design of Experiment and Machine Learning. Claes, Ness, Elf, Dasher, Tinsel, and Menorah
Prof Laura Menorah’s team at the Univ Northpole uses DoE to optimize Mrs. Claus’ eggnog recipe.

Proc Natl Acad Sci Northpole 2013. 12:25-31. KRISPR-KRINGLEi Utilized for Leptin Supression in Elves (Denisova hominin). Kane, Claes, Ness, Elf, Dasher, and Menorah
Prof Laura Menorah’s team at the Univ Northpole utilizes the CRISPR system to improve Elf health.

Proc Natl Acad Sci Northpole 2012. 12:25-31. Deconvolution of Inherent Genomic-Melodic Linkages, or The Music of Life. Claes, Navidad, Ness, Elf, Dasher, Tinsel and Menorah
Prof Laura Menorah’s team at the Univ Northpole explores the relationship between ancestral genomic information and musical annotation.

Proc Natl Acad Sci Northpole 2011. 12:25-31. Nine improved monomeric fluorescent proteins from Rangifer tarandus. Claes, Navidad, Ness, Elf, Dasher, Tinsel and Menorah
Prof Laura Menorah's team at the Univ Northpole has used whole genome sequencing and genome-wide functional association studies to identify the red fluorescent protein, Rudolph. Directed evolution and protein engineering (ProteinGPS) further identified eight additional colors. The reindeer proteins are in the public domain and sold under the BioBrick Public Agreement.

Proc Natl Acad Sci Northpole 2010. 12:25-31. Carolome: Functional Imprints of Culture Memes in Global Genome. Claes, Navidad, Ness, Baum, Elf, Dasher, and Menorah
A research team lead by Prof Laura Menorah at the Univ Northpole has systematically identified Christmas carols deposited in sequence data, and established their direct role in the functional imprint and transfer of genetic information. They name this exciting new field of research Carolomics.

Nature 2009. 458:703. For anyone who ever said there's no such thing as a poetic gene. Gustafsson
Correspondence to Nature regarding poetry in synthetic genomes.

Proc Natl Acad Sci Northpole 2008 12:25-31. Metabolic engineering of Picea abies for receptor mediated induction of fluorescence and olfactory signaling. Claes, Navidad, Ness, Baum, Harry, Dasher, and Elf
In a concerted synthetic biology and tissue engineering effort, a team lead by Santa Claes at the Univ Northpole designed and constructed a christmas tree that induced endogenous fluorescent sparkling and olfactory emission after induction by christmas carols.

Proc Natl Acad Sci Northpole 2006. 12:25. Heterologous expression and functional characterization of the Santa Hoho2 gene. Claes, Reindeer, Nicolas, Tomte, Dasher, Elf
The Hoho2 gene responsible for facial hair formation of Santa Claus is isolated and shown to be an ortholog of human KRT6B. The Hoho2 gene was codon optimized and and the corresponding protein expressed in E. coli, reindeer and human. RNAi knockout constructs could be trans-complemented with an RNAi resistant Hoho2 variant. Brilliant science by Prof Elf and coworkers at Univ Northpole.

Int Pub 2005 12:25 Creation of the Tomten Gene G051225. Claes, Tomte, Dasher, Elf
In an attempt to honor Tomten and investigate its molecular basis, DNA2.0 created the Tomten gene. The gene was codon optimized for expression in Reindeer, synthesized and cloned. Constructs successfully expressed the glowing snow of the Tomten.